Holen Sie sich die Stockscreener-App
3.20
2.56%
0.08
Schlusskurs vom Vortag:
$3.12
Offen:
$3.13
24-Stunden-Volumen:
1.08M
Relative Volume:
0.44
Marktkapitalisierung:
$306.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-84.23M
KGV:
-3.4643
EPS:
-0.9237
Netto-Cashflow:
$-77.15M
1W Leistung:
+2.89%
1M Leistung:
+4.92%
6M Leistung:
-65.67%
1J Leistung:
-14.89%
1-Tages-Spanne:
$3.13
$3.28
1-Wochen-Bereich:
$2.99
$3.42
52-Wochen-Spanne:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Firmenname
Rezolute Inc
Sektor
Branche
Telefon
650-206-4507
Adresse
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.20 | 293.79M | 0 | -84.23M | -77.15M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-12-11 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-08-27 | Eingeleitet | Guggenheim | Buy |
| 2024-07-17 | Eingeleitet | BTIG Research | Buy |
| 2024-06-04 | Eingeleitet | Craig Hallum | Buy |
| 2024-04-09 | Eingeleitet | Maxim Group | Buy |
| 2022-08-02 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-27 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Rezolute Inc Aktie (RZLT) Neueste Nachrichten
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout - MSN
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
Rezolute, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
RZLT (Rezolute Inc.) drops 2.26% after Q1 2026 earnings report reveals wider than expected per-share loss. - Xã Vĩnh Công
RZLT (Rezolute Inc.) reports wider than expected Q1 2026 loss, shares edge higher even as earnings miss analyst estimates.High Volatility - UBND thành phố Hải Phòng
Rezolute (RZLT) Top Gainer | Q1 2026: Earnings UnderperformRegulatory Risk - Cổng thông tin điện tử tỉnh Lào Cai
Rezolute gains after positive FDA meeting over lead asset - MSN
Xoma Royalty Corporation Investigated by the Portnoy Law Firm - GlobeNewswire
Rezolute to present Phase 3 ersodetug data at medical meeting By Investing.com - Investing.com Australia
Rezolute to present Phase 3 ersodetug data at medical meeting - Investing.com
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting - The Manila Times
NervGen Pharma Corp. (NGEN) - Minichart
Rezolute (RZLT) Stock Under Pressure (Investor Concern) 2026-04-20Popular Trader Picks - Cổng thông tin điện tử Tỉnh Sơn La
Free cash flow per share of Rezolute, Inc. – MUN:6HV1 - TradingView
Rezolute (RZLT) Stock: Valuation Gap (-2.26%) 2026-04-18Correlation Analysis - Cổng thông tin điện tử tỉnh Tây Ninh
Rezolute, Inc. (NASDAQ:RZLT) Short Interest Down 21.2% in March - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Rezolute: Caught Between Biology And Statistics, Initiating With Hold Rating (NASDAQ:RZLT) - Seeking Alpha
FDA flexibility isn’t absent but evolving regulations come with growing pains - BioSpace
Rezolute’s Phase 3 SunRIZE study for Ersodetug fails to meet primary and secondary endpoints despite analyst backing - MSN
Rezolute Insider Confidence Rewarded, Stock Hits US$379m Market Cap - simplywall.st
Risk On: Is Rezolute Inc a top pick in the sectorFed Meeting & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Price Action: Will Rezolute Inc stock go up in YEARDollar Strength & Weekly Market Pulse Updates - baoquankhu1.vn
RZLT Q2 2026 Earnings: Rezolute Inc. posts wider-than-expected loss, reports no revenue - UBND thành phố Hải Phòng
Rezolute stock gains after FDA meeting on Ersodetug program update - MSN
RZLT.O PE Ratio & Valuation, Is RZLT.O Overvalued - Intellectia AI
RZLT Technical Analysis & Stock Price Forecast - Intellectia AI
Rezolute, Inc. (RZLT) stock price, news, quote and history - Yahoo Finance UK
What is HC Wainwright's Estimate for Rezolute Q1 Earnings? - MarketBeat
Rezolute CFO Evans Daron buys $28,500 in RZLT stock By Investing.com - Investing.com South Africa
Rezolute CFO Evans Daron buys $28,500 in RZLT stock - Investing.com
Rezolute (RZLT) CFO adds 10,000 shares in open-market purchase - Stock Titan
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart - Capital.com
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Rezolute: Sell Rating Despite FDA Feedback From Type B Meeting For Ersodetug (NASDAQ:RZLT) - Seeking Alpha
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Will Rezolute Inc outperform during market ralliesTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Opaleye Management Inc.'s Rezolute Inc(RZLT) Holding History - GuruFocus
Volume Report: Will Rezolute Inc stock go up in YEAR2026 Dividend Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Vanguard realigns reporting; no beneficial stake in Rezolute (RZLT) - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
Rezolute (RZLT) Gains Upgrade Following Positive FDA Meeting - GuruFocus
Finanzdaten der Rezolute Inc-Aktie (RZLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):